What Next for uniQure N.V. (QURE) After Forming Bullish Wedge Up?

June 23, 2018 - By Adrian Mccoy

uniQure N.V. (NASDAQ:QURE) Logo

The stock of uniQure N.V. (QURE) formed an up wedge with $37.63 target or 4.00 % above today’s $36.18 share price. The 7 months wedge indicates low risk for the $1.34 billion company. If the $37.63 price target is reached, the company will be worth $53.64 million more.
Rising wedges, especially for downward breakouts are tricky moments to trade. Investors must be aware that the break even failure rate for up or down breakouts is: 8% and 24%. The average rise is 28% and the decline is 14%. Wedges has high throwback and pullback rate: 73%, 63% and the percent of wedges meeting target is not more than 50%.

The stock decreased 8.41% or $3.32 during the last trading session, reaching $36.18. About 449,620 shares traded or 20.02% up from the average. uniQure N.V. (NASDAQ:QURE) has risen 534.87% since June 24, 2017 and is uptrending. It has outperformed by 522.30% the S&P500.

Analysts await uniQure N.V. (NASDAQ:QURE) to report earnings on August, 14. They expect $-0.64 earnings per share, up 22.89 % or $0.19 from last year’s $-0.83 per share. After $-0.59 actual earnings per share reported by uniQure N.V. for the previous quarter, Wall Street now forecasts 8.47 % negative EPS growth.

uniQure N.V. (NASDAQ:QURE) Ratings Coverage

Among 6 analysts covering uniQure NV (NASDAQ:QURE), 6 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. uniQure NV had 7 analyst reports since January 3, 2018 according to SRatingsIntel. The firm has “Buy” rating by Wells Fargo given on Wednesday, May 16. Janney Capital initiated it with “Buy” rating and $25.0 target in Wednesday, January 3 report. Janney Capital maintained the shares of QURE in report on Tuesday, March 20 with “Buy” rating. Leerink Swann maintained the stock with “Buy” rating in Monday, May 7 report. The firm earned “Buy” rating on Thursday, March 15 by H.C. Wainwright. The company was maintained on Wednesday, May 23 by Chardan Capital Markets.

More notable recent uniQure N.V. (NASDAQ:QURE) news were published by: Globenewswire.com which released: “uniQure Announces New Appointments to its Board of Directors” on June 13, 2018, also Benzinga.com with their article: “Benzinga’s Daily Biotech Pulse: AbbVie Launches New Pediatric Humira, IPO Deluge Hits The Street” published on June 21, 2018, Streetinsider.com published: “uniQure (QURE) Reports Issuance of New Patents Providing Broad Protection of Padua Variant of Factor IX in Gene …” on May 29, 2018. More interesting news about uniQure N.V. (NASDAQ:QURE) were released by: Streetinsider.com and their article: “uniQure (QURE) Appoints Robert Gut, MD, Ph.D. and David Meek to Board” published on June 13, 2018 as well as Nasdaq.com‘s news article titled: “Analysis: Positioning to Benefit within Willis Towers Watson Public, MyoKardia, Texas Capital Bancshares, uniQure NV …” with publication date: June 06, 2018.

uniQure N.V., a biopharmaceutical company, engages in the discovery, development, and commercialization of gene therapies in the Netherlands. The company has market cap of $1.34 billion. The companyÂ’s principle programs include AMT-060, a gene therapy that has completed Phase I/II clinical trial for the treatment of hemophilia B; S100A1, a preclinical product candidate for the treatment of congestive heart failure; and AMT-130 for the treatment of huntington's disease. It currently has negative earnings. It also provides Glybera, a gene therapy product that has approved for the treatment of patients with lipoprotein lipase deficiency.

uniQure N.V. (NASDAQ:QURE) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: